Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.

Cancer · 2026 · PMC12976832 · PMID 41808570

Europe PMC DOI

hedged sentences

0.0725

closest p · 1.4× alpha

0.0949

boldest claim

The sentences

a favorable trendp = .0725so close (0.05 < p ≤ 0.1)

12 A favorable trend toward cemiplimab was also observed in TTD analysis of GHS/QoL for the overall population (HR, 0.70; 95% CI, 0.48–1.04; p = .0725). 6 Change from baseline in GHS/QoL scores by disease progression and objective response For the two treatment arms combined (the overall population), GHS/QoL scor

also in 1,335 other papers

a numerical trendp = .0949so close (0.05 < p ≤ 0.1)

A numerical trend favoring cemiplimab was observed in GHS/QoL in the ECOG PS 1 subgroup (HR, 0.66; 95% CI, 0.41–1.08; p = .0949) 16 and in the subgroup with PD‐L1 expression from >60% to <90% (HR, 0.62; 95% CI, 0.33–1.17; p = .1336). 12 A favorable trend toward cemiplimab was also observed in TTD analysis of

also in 1,012 other papers

did not reach statistical significanceno p-value reported

Also, whereas some estimated HRs strongly favored cemiplimab over chemotherapy (e.g., an HR of 0.66 in the ECOG PS 1 subgroup), they did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.